Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 9/20 | 0.37 |
| ▸ | RAB9A | P51151 | 9/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981917 | 0.84 | TP53 (0.44) | NPC1RAB9AKMT2AMEN1ELANE | |
| SCHEMBL30376133 | 0.80 | NPC1 (0.46) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL17632197 | 0.80 | NPC1 (0.46) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL12601110 | 0.79 | MAP2K4 (0.41) | CYP11B2MAP2K4NPC1RAB9ASCN9A | |
| SCHEMBL1161618 | 0.78 | NPC1 (0.52) | CYP11B2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1743109 | 0.78 | MAP2K4 (0.41) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL29510728 | 0.77 | MAP2K4 (0.45) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL21223059 | 0.77 | MAP2K4 (0.47) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL2478647 | 0.77 | MAP2K4 (0.45) | MAP2K4NPC1RAB9ASCN9ASCN5A | |
| SCHEMBL3695671 | 0.77 | KMT2A (0.46) | MAP2K4NPC1RAB9ASCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2513095-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | CYP11B2 253/4885MAP2K4 3386/4885NPC1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.